LRT Capital Management LLC Has $1.18 Million Stock Holdings in Novo Nordisk A/S $NVO

LRT Capital Management LLC lifted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 203.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,222 shares of the company’s stock after purchasing an additional 14,239 shares during the quarter. LRT Capital Management LLC’s holdings in Novo Nordisk A/S were worth $1,178,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Franklin Resources Inc. raised its stake in Novo Nordisk A/S by 4,190.8% during the 3rd quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock worth $776,016,000 after buying an additional 13,658,867 shares during the period. Capital International Investors grew its stake in Novo Nordisk A/S by 52.4% in the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after acquiring an additional 6,092,192 shares during the period. Boston Partners bought a new stake in shares of Novo Nordisk A/S in the third quarter worth about $310,199,000. SG Americas Securities LLC increased its holdings in shares of Novo Nordisk A/S by 2,101.5% in the third quarter. SG Americas Securities LLC now owns 2,383,176 shares of the company’s stock worth $132,242,000 after acquiring an additional 2,274,925 shares in the last quarter. Finally, Clear Street Group Inc. acquired a new stake in shares of Novo Nordisk A/S during the third quarter worth about $56,378,000. 11.54% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on NVO. Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. TD Cowen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price for the company. in a research note on Tuesday, March 10th. Nordea Equity Research downgraded shares of Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Finally, Kepler Capital Markets lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Tuesday, February 24th. Four research analysts have rated the stock with a Buy rating and nineteen have given a Hold rating to the company. According to MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Hold” and an average target price of $49.93.

Novo Nordisk A/S Stock Up 1.6%

NYSE:NVO opened at $38.57 on Tuesday. The stock has a 50-day simple moving average of $49.81 and a 200 day simple moving average of $51.61. Novo Nordisk A/S has a 52-week low of $35.85 and a 52-week high of $82.57. The company has a market cap of $172.22 billion, a PE ratio of 11.12 and a beta of 0.74. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The firm had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. On average, sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be given a $1.2751 dividend. This represents a dividend yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s payout ratio is currently 23.63%.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.